Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are comparing the study drug sacituzumab govitecan SG Trodelvy to standard treatments in people with extensive stage small cell lung cancer ES-SCLC who have already received prior therapy. The main goal is to see which treatment helps participants live longer by measuring overall survival. This is a global, randomized, open-label Phase 3 trial conducted to evaluate the effects of SG versus standard care in this patient population. Participants in the study are randomly assigned to one of two treatment groups. Group A receives sacituzumab govitecan intravenously at 10 mgkg on Days 1 and 8 of each 21-day cycle. Group B receives one of several approved standard treatments chosen by the investigator, including topotecan, lurbinectedin where available, or amrubicin in Japan, administered according to usual schedules in 21-day cycles. Treatment continues until disease worsens, unacceptable side effects occur, death, or other reasons for stopping treatment. During the study, participants undergo regular assessments including imaging scans to measure tumor response, physical evaluations, and laboratory tests to monitor safety. Researchers track important outcomes such as progression-free survival, response rates, duration of response, and quality of life measures related to breathing and physical function for up to 4.5 years. Safety is closely monitored by recording adverse events and laboratory abnormalities throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating overall survival in patients with advanced metastatic or locally recurrent breast cancer who have no approved alternative therapies available. This Phase 3, multicenter, randomized, open-label study compares the Bria-IMT regimen combined with the checkpoint inhibitor Retifanlimab against treatment chosen by patients or physicians, known as Treatment of Physicians Choice TPC. The study also investigates the activity of the Bria-IMT regimen alone compared to its combination with Retifanlimab. Participants are initially randomized into three groups Bria-IMT regimen plus Retifanlimab combination therapy, TPC, and Bria-IMT regimen alone monotherapy. After enrolling the first 150 patients, the monotherapy group will be discontinued, and those patients may switch to combination therapy. The Bria-IMT regimen includes cyclophosphamide administered 2-3 days before SV-BR-1-GM given intradermally in four inoculations, followed by checkpoint inhibitor infusion plus interferon injections at inoculation sites over three days. Treatment cycles repeat every three weeks, while TPC is given per standard care at each site. Imaging assessments are conducted every six weeks twice, then every eight weeks thereafter unless disease progression or safety issues occur. During the study, participants will have regular therapy cycles and imaging assessments to monitor disease progression. Researchers will evaluate outcomes such as overall survival up to 60 months, progression-free survival, clinical benefit rate, overall response rate, quality of life, and central nervous system event-free survival. Safety and treatment effects will be closely monitored throughout the trial, which is expected to complete by June 2028.
Actively Recruiting
Researchers are studying a new medicine called PF-08634404 to see how well it works when combined with chemotherapy in adults who have extensive-stage small cell lung cancer ES-SCLC, a fast-growing type of lung cancer that has spread widely. This study includes two parts the first part focuses on checking the safety and tolerance of the medicine with chemotherapy, while the second part compares this combination to an approved treatment using atezolizumab and chemotherapy. Participants will receive treatments through intravenous infusions in repeated cycles. Some participants may continue receiving PF-08634404 alone after the initial combined treatment phase. The study involves random assignment to either the PF-08634404 plus chemotherapy group or the atezolizumab plus chemotherapy group. During the study, participants will have regular assessments including scans to measure tumor response, physical exams, laboratory tests, and questionnaires to evaluate quality of life. The researchers will track outcomes such as tumor shrinkage, overall survival, adverse events, and treatment tolerance up to about two years after treatment completion. Safety and drug concentration in the blood will also be monitored closely throughout the trial.
Actively Recruiting
Researchers are studying a sequential treatment strategy for adults with HER2-positive and hormone receptor-positive advanced or metastatic breast cancer. The goal is to maximize disease control, optimize tolerability, and preserve trastuzumab deruxtecan T-DXd as a future treatment option. This global, open-label phase 3b trial assesses the effectiveness and safety of this approach, as well as quality-of-life outcomes. The treatment begins with upfront therapy combining T-DXd and pertuzumab given intravenously every three weeks for 18 to 24 cycles. Then participants transition to maintenance therapy with trastuzumab, pertuzumab, endocrine therapy, and oral palbociclib. If the disease progresses during maintenance, participants may receive retreatment with T-DXd monotherapy every three weeks. Dose reductions during upfront treatment will be maintained. Participants will be monitored through regular imaging and clinical assessments to measure progression-free survival and response rates up to 24 months. Quality-of-life questionnaires will track changes during treatment phases. Safety will be observed by recording adverse events during all treatment periods, including retreatment. The entire study spans several years, with follow-up to evaluate long-term outcomes and tolerability.